Edition:
United States

Akebia Therapeutics Inc (AKBA.OQ)

AKBA.OQ on NASDAQ Stock Exchange Global Market

15.79USD
21 Nov 2017
Change (% chg)

$0.30 (+1.94%)
Prev Close
$15.49
Open
$15.59
Day's High
$15.83
Day's Low
$15.59
Volume
106,643
Avg. Vol
139,086
52-wk High
$20.25
52-wk Low
$7.78

Chart for

About

Akebia Therapeutics, Inc. is a biopharmaceutical company. The Company focuses on the development and commercialization of therapeutics based on hypoxia-inducible factor (HIF) biology. The Company's lead product candidate, vadadustat, is indicated for the treatment of anemia in chronic kidney disease (CKD). It is involved in... (more)

Overall

Beta: 1.00
Market Cap(Mil.): $732.20
Shares Outstanding(Mil.): 47.27
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 200.64 15.49
EPS (TTM): -- -- --
ROI: -- -10.01 11.95
ROE: -- -35.77 15.94

BRIEF-Akebia Therapeutics reports Q3 loss per share $0.49

* Akebia Therapeutics announces third quarter 2017 financial results

Nov 08 2017

BRIEF-Invirsa secures seed financing to develop new approach

* Invirsa secures seed financing to develop new approach to treating common infectious diseases that affect millions annually Source text for Eikon: Further company coverage:

Nov 07 2017

Insider trading suspect out of U.S. jail as judge weighs 'Jekyll & Hyde' risk

BOSTON A former Akebia Therapeutics Inc employee accused of insider trading was released from jail on Thursday despite a judge's concern that the man's "Dr. Jekyll and Mr. Hyde" tendencies could lead him to violate his bail conditions.

Oct 12 2017

Insider trading suspect out of U.S. jail as judge weighs 'Jekyll & Hyde' risk

BOSTON, Oct 12 A former Akebia Therapeutics Inc employee accused of insider trading was released from jail on Thursday despite a judge's concern that the man's "Dr. Jekyll and Mr. Hyde" tendencies could lead him to violate his bail conditions.

Oct 12 2017

Ex-Akebia employee suspected of insider trading re-arrested

BOSTON A former Akebia Therapeutics Inc employee accused of insider trading was re-arrested on Friday after violating a bail condition as a prosecutor who once called him "increasingly unhinged" said he would seek the man's detention pending trial.

Sep 22 2017

Ex-Akebia employee suspected of insider trading re-arrested

BOSTON, Sept 22 A former Akebia Therapeutics Inc employee accused of insider trading was re-arrested on Friday after violating a bail condition as a prosecutor who once called him "increasingly unhinged" said he would seek the man's detention pending trial.

Sep 22 2017

Ex-Akebia employee faces losing bail in insider trading case

BOSTON A former Akebia Therapeutics Inc employee accused of insider trading faced the growing possibility of having his bail revoked as a U.S. prosecutor argued on Thursday that he posed a flight risk and was growing "increasingly unhinged."

Jul 20 2017

Ex-Akebia employee faces losing bail in insider trading case

BOSTON A former Akebia Therapeutics Inc employee accused of insider trading faced the growing possibility of having his bail revoked as a U.S. prosecutor argued on Thursday that he posed a flight risk and was growing "increasingly unhinged."

Jul 20 2017

Ex-Akebia employee faces losing bail in insider trading case

BOSTON, July 20 A former Akebia Therapeutics Inc employee accused of insider trading faced the growing possibility of having his bail revoked as a U.S. prosecutor argued on Thursday that he posed a flight risk and was growing "increasingly unhinged."

Jul 20 2017

BRIEF-Muneer Satter reports 6.48 pct stake in Akebia Therapeutics

* Muneer Satter reports 6.48 percent stake in Akebia Therapeutics Inc as of July 5 - SEC filing

Jul 14 2017

Earnings vs. Estimates